🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

24 results for “Gain” Clear

  1. ALXN1720 Placebo Product, Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  2. Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  3. ziltivekimab, Ziltivekimab

    Novo Nordisk A/S

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    phase 3 small molecule active

    1 trial

  4. Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/​Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Multiple Myeloma

    phase 2 other active

    1 trial

  5. HUMAN IGG1 LAMBDA MONOCLONAL ANTIBODY AGAINST ALFA-SYNUCLEIN, SALINE, HUMAN IGG1 LAMBDA MONOCLONAL ANTIBODY AGAINST ALFA-SYNUCLEIN

    Takeda Pharmaceuticals International AG

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

  6. Humanized IgG1 monoclonal antibody against GD2, Leukine

    Y-Mabs Therapeutics A/S

    Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow

    phase 2 small molecule active

    1 trial

  7. Low Dose GT-02287

    Gain Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  8. Mifepristone

    CORCEPT THERAPEUTICS INC

    Weight-Gain Prevention

    phase 2 small molecule completed

    1 trial

  9. Miricorilant

    CORCEPT THERAPEUTICS INC

    Antipsychotic-induced Weight Gain (AIWG)

    phase 2 small molecule completed

    1 trial

  10. Miricorlilant

    CORCEPT THERAPEUTICS INC

    Antipsychotic-induced Weight Gain (AIWG)

    phase 2 small molecule completed

    1 trial

  11. Placebo to MAS825 100 mg/1 mL Concentrate for solution for infusion / Solution for injection, -, CICLOSPORIN , MAS825

    Novartis Ophthalmics Europe

    Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.

    phase 2 small molecule active

    1 trial

  12. TREDIMIN 25.000 U.I. /2,5 ml soluzione orale

    Sana Biotechnology

    haematologic condition who need staminal cells transplant

    phase 2 small molecule active

    1 trial

  13. TX200-TR101

    SANGAMO THERAPEUTICS, INC

    Prophylaxis against renal transplant rejection

    phase 2 small molecule active

    1 trial

  14. A Phase I Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 against Crimean Congo Hemorrhagic Fever (CCHF-NP-1)

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Crimean Congo Hemorrhagic Fever

    phase 1 other active

    1 trial

  15. A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults.

    GlaxoSmithKline Biologicals S.A.

    Respiratory Syncytial Virus Infections

    phase 1 other active

    1 trial

  16. A study to learn how safe the study drug BAY 2416964 (AhR inhibitor) in combination with the treatment pembrolizumab is, how this combination affects the body, the maximum amount that can be given, how it moves into, through and out of the body and its action against advanced solid cancers in adults

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  17. GT-02287

    Gain Therapeutics

    Parkinson Disease

    phase 1 small molecule active

    1 trial

  18. Miricorilant

    CORCEPT THERAPEUTICS INC

    Antipsychotic Induced Weight Gain

    phase 1 small molecule completed

    1 trial

  19. Olanzapine

    CORCEPT THERAPEUTICS INC

    Antipsychotic-induced Weight Gain

    phase 1 small molecule completed

    1 trial

  20. Safety and immune responses after vaccination with two investigational RNA-based vaccines against tuberculosis in healthy volunteers

    BioNTech Manufacturing GmbH

    Tuberculosis

    phase 1 other active

    1 trial

  21. INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Influenza, Immunity against influenza

    approved small molecule active

    1 trial

  22. Naltrexone HCl/Bupropion HCl Placebo

    Takeda Pharmaceuticals International AG

    Weight Regain Post Bariatric Surgery

    approved small molecule terminated

    1 trial

  23. Dairy based toddler nutrition

    United Therapeutics Europe Ltd

    Weight Gain

    other active

    1 trial

  24. Envita Stories Methodology in Long-term care Centres for old adults

    Gain Therapeutics

    Long-term Care Centres for Old Adults Users

    other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources